Orange Book product · Generic (ANDA)
CEVIMELINE HYDROCHLORIDE
CEVIMELINE HYDROCHLORIDE
At a glance
Sep 20, 2024
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 20, 2024
1 yr 9 mo ago
Today
Pharmaceutical detail
Active ingredient
CEVIMELINE HYDROCHLORIDE
Strength
30MG
Dosage form
CAPSULE
Route
ORAL
TE code
AB
Application
ANDA 206808
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of CEVIMELINE HYDROCHLORIDE
- 2000EVOXACBrand (NDA)
NDA 020989 · COSETTE
- 2026CEVIMELINE HYDROCHLORIDEGeneric (ANDA)
ANDA 220267 · ZYDUS LIFESCIENCES
- 2023CEVIMELINE HYDROCHLORIDEGeneric (ANDA)
ANDA 218290 · BIONPHARMA
- 2023CEVIMELINE HYDROCHLORIDEGeneric (ANDA)
ANDA 215056 · AUROBINDO PHARMA
- 2023CEVIMELINE HYDROCHLORIDEGeneric (ANDA)
ANDA 216682 · RUBICON RESEARCH
- 2016CEVIMELINE HYDROCHLORIDEGeneric (ANDA)
ANDA 204746 · NOVEL LABS INC
- 2014CEVIMELINE HYDROCHLORIDEGeneric (ANDA)
ANDA 203775 · RISING
- 2013CEVIMELINE HYDROCHLORIDEGeneric (ANDA)
ANDA 091591 · HIKMA
- 2011CEVIMELINE HYDROCHLORIDEGeneric (ANDA)
ANDA 091260 · APOTEX INC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
